Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study of LY3127760 in Healthy Participants
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2013-10-23
- Last Posted Date
- 2019-06-07
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 80
- Registration Number
- NCT01968070
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Evansville, Indiana, United States
A Study of LY2157299 in Healthy Participants
- Conditions
- Healthy Volunteers
- Interventions
- Drug: LY2157299
- First Posted Date
- 2013-10-18
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 16
- Registration Number
- NCT01965808
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Daytona Beach, Florida, United States
A Study of [14C]-LY3023703 in Healthy Participants
- Conditions
- Healthy Volunteers
- Interventions
- Drug: [^14C]-LY3023703
- First Posted Date
- 2013-10-18
- Last Posted Date
- 2018-08-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 18
- Registration Number
- NCT01965782
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madison, Wisconsin, United States
Evaluate the Immunogenicity of a Novel Glucagon Formulation
- Conditions
- Drug-specific AntibodiesDiabetes Mellitus
- Interventions
- Drug: Glucagon IMDrug: Nasal Glucagon (NG)
- First Posted Date
- 2013-10-10
- Last Posted Date
- 2019-09-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 75
- Registration Number
- NCT01959334
- Locations
- 🇨🇦
Algorithme Pharma Inc., Laval, Quebec, Canada
A Study of Baricitinib and Simvastatin in Healthy Participants
- First Posted Date
- 2013-10-10
- Last Posted Date
- 2017-06-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 40
- Registration Number
- NCT01960140
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leeds, West Yorkshire, United Kingdom
A Study of Evacetrapib in Japanese and Non-Japanese Participants
- First Posted Date
- 2013-10-09
- Last Posted Date
- 2018-10-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 24
- Registration Number
- NCT01958489
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leeds, West Yorkshire, United Kingdom
A Safety Study of Mirikizumab (LY3074828)
- Conditions
- Psoriasis
- Interventions
- Biological: Placebo - IVBiological: Mirikizumab - SCBiological: Mirikizumab- IV
- First Posted Date
- 2013-09-23
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 45
- Registration Number
- NCT01947933
- Locations
- 🇨🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Montreal, Quebec, Canada
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED)
- Conditions
- Benign Prostate HyperplasiaErectile Dysfunction
- Interventions
- Drug: PlaceboDrug: 5 mg TadalafilDrug: 0.2 mg Tamsulosin
- First Posted Date
- 2013-09-10
- Last Posted Date
- 2017-06-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 909
- Registration Number
- NCT01937871
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Xi'An, China
A Study of Baricitinib and Probenecid in Healthy Participants
- First Posted Date
- 2013-09-09
- Last Posted Date
- 2017-06-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 18
- Registration Number
- NCT01937026
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leeds, West Yorkshire, United Kingdom
A Study of Duloxetine in Participants With Chronic Pain Due to Osteoarthritis in China
- First Posted Date
- 2013-08-29
- Last Posted Date
- 2016-05-23
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 407
- Registration Number
- NCT01931475
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zhuzhou, China